Top
Toll Free : +1 (855) 711-1555       sales@researchbeam.com

Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020

Published :  Allied Market Research
Date :   Dec-2013
Page :   92
GET THIS REPORT
BUY NOW

NEED MORE INFORMATION ?

CALL

+1 1800 2545 145



Demand for innovative diabetic management devices worldwide has increased the adoption of CGM- Continuous Glucose Monitoring Devices. Major reason for rising popularity of CGMs is its efficiencies to stabilize the raised levels of A1C, which reduces the possibilities of a long term diabetic problem. Other factors that drive the growth of CGM market are innovative technologies such as artificial pancreas, rising awareness in developed, under developed and developing nations, and rise in cases of diabetics. However, lack of reimbursements policies for CGM, stringent government regulations, lack of accuracy and higher costs are restricting the growth of market.

In the year 2012, global continuous glucose monitors market stood at $194.8 million. The report forecasts the market to reach $568.5 million by 2020, registering a CAGR of 14.8% during 2013-2020.

SEGMENT ANALYSIS

In the product segment analysis, insulin pump market would witness fastest growth followed by glucose sensors market. Factor that drives the growth of insulin pump market is insulin integration with CGMs, which is an important step to close the loop algorithm. Further, the need to replace glucose sensors after every 4 to 7 days, glucose sensors market would generate maximum revenues during the projected period.

In terms of application market, Global CGM market consist of Diagnostics, Hospitals and Home settings. Home setting segment,, would be the maximum revenue generators by 2020.

North America is the leading geographical region in terms of revenue due to earlier adoption of advanced technology, higher adoption, reimbursements and rising patient pool. However, Asia Pacific would be the fasted growing geographical region owing to its rising patient pool, rise in incomes, and increasing penetration of key firms and rising standard of livings.

Top companies in the CGM market are Medtronics, Animas Corporation,Dexcom,Ypsomed AG, Miraculins, Inc and Omnipodcomprising others. Key strategies implemented by the market players are Collaborations, approvals and Product launches.

KEY BENEFITS OF THE REPORT

  • The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self-monitoring glucose devices, approval for artificial pancreas and many more
  • Market is forecast for 2013 -2020, with market revenues for 2 historic years of 2010 and 2012
  • Identification and analysis of of nvestment pockets for CGM manufacturers
  • Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market
  • Analysis of regulatory framework that controls the newly lauched CGM devices and provides you with detailed information on reimbursement policies
  • The report identifies and profiles key market participants who would drive innovation in the CGM market




CHAPTER 1 INTRODUCTION



1.1 Objectives and Scope

1.2 Report Description

1.3 Key Benefits of the Report

1.4 Research Methodology



CHAPTER 2 EXECUTIVE SUMMARY



CHAPTER 3 GLOBAL CONTINUOUS GLUCOSE MONITORS MARKET OVERVIEW



3.1 Healthcare Expenditure on Diabetes Worldwide

3.2 Type-1 Diabetics to Remain Key Target for CGM Market



3.2.1 Type-1 Diabetes



3.2.1.1 Type-1 Diabetes in Young People



3.2.2 Type-2 Diabetes



3.2.2.1 Type-2 Diabetes in Young People



3.2.3 Gestational Diabetes

3.2.4 Other Types of Diabetes



3.3 Market Intelligence



3.3.1 Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020



3.3.1.1 Fda Approval of Artificial Pancreas

3.3.1.2 Convenience Offered by CGM Over Self Monitoring Glucose Devices

3.3.1.3 Rise in Incidences of Diabetes Cases Globally

3.3.1.4 Earlier Detection of the Hypo and Hyperglycemic Events by CGM

3.3.1.5 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption

3.3.1.6 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM

3.3.1.7 Strict Regulatory Impositions

3.3.1.8 Increase in Awareness Among Developing and Underdeveloped Economies



3.3.2 Top Three Winning Strategies in the Continuous Glucose Monitors Market

3.3.2.1 Global Market Players Positioning

3.3.3 Top Investment Pockets in Continuous Glucose Monitors Market



3.3.3.1 Continuous Glucose Monitors Market – by Device

3.3.3.2 Continuous Glucose Monitors Market – by Applications

3.3.3.3 Continuous Glucose Monitors Market – by Geography



3.4 Regulations

3.5 Reimbursement Scenario

3.6 Market Dynamics



3.6.1 Drivers



3.6.1.1 Convenience Offered by CGM Over Self Monitoring Glucose Devices

3.6.1.2 FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System

3.6.1.3 Earlier Detection of the Hypo and Hyperglycemic Events by CGM

3.6.1.4 Rise in Incidences of Diabetes Cases Globally

3.6.1.5 Increase in Awareness Among the Population in Developing and Underdeveloped Economies



3.6.2 Restraints



3.6.2.1 Strict Regulatory Impositions

3.6.2.2 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption

3.6.2.3 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM



3.6.3 Market Opportunity



3.6.3.1 Growth in Emerging Market



3.6.4 Winning Strategies for Mncs in Emerging Markets



3.6.4.1 Tailoring the Existing Products to the Local Market Needs

3.6.4.2 Adoption of a Proactive Hybrid Model Rather Than Distributor Management

3.6.4.3 Service Rendered Makes a Difference

3.6.4.4 Partnership and Acquisition Key to Enhance Reach and Market Position

3.6.4.5  Adopting An Emerging-Market Attitude



CHAPTER 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY DEVICES



4.1 Transmitter and Receivers

4.2 Sensors



4.2.1 Market Trend



4.2.1.1 Non-Invasive Glucose Sensors

4.2.1.2 Subcutaneous Sensors (Minimally Invasive Sensors)

4.2.1.3 Conventional Technology – Holter-Type Retrospective Sensors

4.2.1.4 Advanced Technology – Real-Time Sensors



4.3 Insulin Pump



4.3.1 Advantages of Insulin Pump

4.3.2 Disadvantages of Insulin Pump

4.3.3 Market Trend



CHAPTER 5 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET - BY APPLICATION



5.1 Diagnostics/Clinics

5.2 Hospitals

5.3 Home Settings

5.4 Role of CGM in Private Practice



5.4.1 Team Members

5.4.2 Clinical Space

5.4.3 Scheduling

5.4.4 Keeping the Patients Informed



CHAPTER 6 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET – BY AGE



6.1 Children and Teens

6.2 Youth

6.3 Middle Elderly and Aged



CHAPTER 7 CGM SYSTEMS MARKET BY GEOGRAPHY



7.1 North America

7.2 Europe

7.2.1 Financial Cost Incurred

7.3 Asia Pacific

7.4 Row



CHAPTER 8 COMPANY PROFILES



8.1 Medtronic Inc.



8.1.1 Company Overview

8.1.2 Company Snapshot

8.1.3 Business Performance

8.1.4 Strategic Moves and Developments



8.1.4.1 Principal Strategies: Product Launch

8.1.4.2 Secondary Strategies: Approval

8.1.4.3 Other Strategies: Collaboration



8.1.5 SWOT Analysis & Strategic Conclusions



8.2 Dexcom Inc.



8.2.1 Company Overview

8.2.2 Company Snapshot

8.2.3 Business Performance

8.2.4 Strategic Moves and Developments



8.2.4.1 Principal Strategies: Agreement/Partnership

8.2.4.2 Secondary Strategies: Acquisition



8.2.5 SWOT Analysis & Strategic Conclusions



8.3 Novo Nordisk



8.3.1 Company Profile

8.3.2 Company Snapshot

8.3.3 Strategic Moves and Developments

8.3.4 SWOT Analysis & Strategic Conclusions



8.4 Spring Health Solution Ltd



8.4.1 Company Profile

8.4.2 Company Snapshot

8.4.3 Strategic Moves and Developments



8.4.3.1 Principal Strategies



8.4.4 SWOT Analysis & Strategic Conclusions



8.5 Roche



8.5.1 Company Profile

8.5.2 Company Snapshot

8.5.3 Strategic Moves and Developments

8.5.4 SWOT Analysis & Strategic Conclusions



8.6 Animas Corporation



8.6.1 Company Profile

8.6.2 Company Snapshot

8.6.3 Strategic Moves and Developments



8.6.3.1 Principal Strategies



8.6.4 SWOT Analysis & Strategic Conclusions



8.7 Ypsomed AG



8.7.1 Company Profile

8.7.2 Company Snapshot

8.7.3 Strategic Moves and Developments



8.7.3.1 Principal Strategies: Product Expansion

8.7.3.2 Secondary Strategies: New Subsidiary

8.7.3.3 Other Strategies: Acquisition and Agreements



8.7.4 SWOT Analysis & Strategic Conclusions



8.8 Insulet Corporation



8.8.1 Company Profile

8.8.2 Company Snapshot

8.8.3 Strategic Moves and Developments



8.8.3.1 Principal Strategies



8.8.4 SWOT Analysis & Strategic Conclusions



 



LIST OF TABLES



TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (AS OF MARCH 2013)

TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (AS OF MARCH 2013)

TABLE 3 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY PRODUCT CATEGORY, 2011-2020, ($MILLION)

TABLE 4 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)

TABLE 5 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)

TABLE 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)

TABLE 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS, 2011 - 2020, ($MILLION)

TABLE 8 GLOBAL CGM MARKET IN DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)

TABLE 9 GLOBAL CGM MARKET IN HOSPITALS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)

TABLE 10 GLOBAL CGM MARKET IN HOME SETTINGS, BY GEOGRAPHY, 2011 - 2020, ($MILLION)

TABLE 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)

TABLE 12 TYPE-1 DIABETES (0-14 YEARS), 2013

TABLE 13 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2013 AND 2020

TABLE 14 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS BY GEOGRAPHY, 2011 - 2020, ($MILLION)

TABLE 15 THE PREVALENCE OF DIABETES IN THE ADULT POPULATION ACROSS THE U.K. IN 2011

TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE

TABLE 17 PREVALENCE ESTIMATES OF DIABETES, 2013 & 2035

TABLE 18 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, AFRICA REGION

TABLE 19 MEDTRONIC BUSINESS SNAPSHOT

TABLE 20 DEXCOM INC. BUSINESS SNAPSHOT

TABLE 21 NOVA NORDISK BUSINESS SNAPSHOT

TABLE 22 SPRING HEALTH SOLUTION LTD BUSINESS SNAPSHOT

TABLE 23 ROCHE BUSINESS SNAPSHOT

TABLE 24 ANIMAS CORPORATION BUSINESS SNAPSHOT

TABLE 25 YPSOMED AG BUSINESS SNAPSHOT

TABLE 26 INSULET CORPORATION BUSINESS SNAPSHOT





LIST OF FIGURES



FIG. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)

FIG. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, 20-79 YEARS ($BILLION)

FIG. 3 TREATMENT OF DIABETES, 2011

FIG. 4 SIMILARITIES IN CAUSE OF PRE-DIABETES AND TYPE-2 DIABETES

FIG. 5 CGM ADOPTION BY DIFFERENT TYPES OF DIABETES PATIENTS

FIG. 6 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)

FIG. 7 GLOBAL PREVALENCE OF TYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCE IN 2030

FIG. 8 TOP FACTORS IMPACTING CGM MARKET, 2013-2020

FIG. 9 TOP WINNING STRATEGY IN CGM MARKET, 2010 TO 2013 (SEPTEMBER)

FIG. 10 TOP WINNING STRATEGY IN CGM MARKET BY YEAR

FIG. 11 GLOBAL MARKET PLAYERS POSITIONING

FIG. 12 TOP INVESTMENT POCKETS IN CGM DEVICE MARKETS

FIG. 13 TOP INVESTMENT POCKETS IN CGM APPLICATION MARKETS

FIG. 14 TOP INVESTMENT POCKETS IN CGM GEOGRAPHY MARKETS

FIG. 15 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)

FIG. 16 GDP PER CAPITA IN EMERGING ECONOMIES

FIG. 17 EMERGING MARKET CAPITALIZATION STRATEGIES

FIG. 18 GLOBAL CGM MARKET AMONG CHILDREN, 2011-2020, ($MILLION)

FIG. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)

FIG. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)

FIG. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)

FIG. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)

FIG. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)

FIG. 24 CASES OF DIABETES BY AGES IN NAC (1000S) (2013 E)

FIG. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)

FIG. 26 CASES OF DIABETES BY AGES IN EUROPE (1000S) (2013 E)

FIG. 27 ASIA PACIFIC CGM MARKET, 2013-2020, ($MILLION)

FIG. 28 TOP 10 COUNTRIES WITH DIABETES INCIDENCES 2013 AND 2035

FIG. 29 ROW CGM MARKET, 2013-2020, ($MILLION)

FIG. 30 FINANCIAL REVENUES BY BUSINESS UNITS (2013)

FIG. 31 FINANCIAL REVENUES BY GEOGRAPHY (2013)

FIG. 32 FINANCIAL REVENUES BY GEOGRAPHY (2012)







Researchbeam  ©2014 Copyright Market Research
Get Social